SRS Capital Advisors Inc. Raises Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

SRS Capital Advisors Inc. grew its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,324 shares of the medical research company’s stock after purchasing an additional 118 shares during the period. SRS Capital Advisors Inc.’s holdings in Thermo Fisher Scientific were worth $1,233,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Sugarloaf Wealth Management LLC grew its position in shares of Thermo Fisher Scientific by 6.9% during the 4th quarter. Sugarloaf Wealth Management LLC now owns 294 shares of the medical research company’s stock valued at $156,000 after buying an additional 19 shares during the last quarter. Rosenberg Matthew Hamilton boosted its stake in shares of Thermo Fisher Scientific by 3.7% during the 4th quarter. Rosenberg Matthew Hamilton now owns 526 shares of the medical research company’s stock worth $279,000 after acquiring an additional 19 shares in the last quarter. Tsfg LLC boosted its holdings in shares of Thermo Fisher Scientific by 8.3% in the fourth quarter. Tsfg LLC now owns 249 shares of the medical research company’s stock worth $132,000 after buying an additional 19 shares during the period. Pacifica Partners Inc. grew its holdings in shares of Thermo Fisher Scientific by 16.5% during the fourth quarter. Pacifica Partners Inc. now owns 141 shares of the medical research company’s stock valued at $69,000 after buying an additional 20 shares in the last quarter. Finally, Retirement Planning Group LLC lifted its position in shares of Thermo Fisher Scientific by 4.9% in the fourth quarter. Retirement Planning Group LLC now owns 446 shares of the medical research company’s stock worth $237,000 after purchasing an additional 21 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock traded down $3.65 during midday trading on Thursday, reaching $571.34. The company had a trading volume of 580,993 shares, compared to its average volume of 1,537,922. The stock has a fifty day simple moving average of $575.03 and a 200 day simple moving average of $531.97. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $218.09 billion, a price-to-earnings ratio of 36.69, a price-to-earnings-growth ratio of 2.36 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.70 by $0.41. The company had revenue of $10.35 billion for the quarter, compared to analyst estimates of $10.14 billion. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. As a group, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 21.64 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were paid a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.27%. The ex-dividend date was Thursday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s dividend payout ratio is presently 10.01%.

Analyst Ratings Changes

TMO has been the topic of several analyst reports. Barclays increased their price target on shares of Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an “equal weight” rating in a research note on Thursday, April 25th. Citigroup initiated coverage on Thermo Fisher Scientific in a research report on Monday, March 18th. They issued a “neutral” rating and a $620.00 price target for the company. HSBC increased their price objective on Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a “buy” rating in a report on Tuesday. Robert W. Baird decreased their target price on Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating for the company in a research report on Thursday, April 25th. Finally, Raymond James lifted their price target on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. Five research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $607.35.

Insider Transactions at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total value of $5,556,300.00. Following the completion of the transaction, the chief executive officer now directly owns 49,155 shares in the company, valued at approximately $27,311,992.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the sale, the senior vice president now owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total value of $5,556,300.00. Following the transaction, the chief executive officer now directly owns 49,155 shares of the company’s stock, valued at approximately $27,311,992.65. The disclosure for this sale can be found here. Insiders have sold a total of 62,277 shares of company stock valued at $35,373,364 over the last three months. 0.34% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.